Biotech | May 16, 2022
Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor
It is developing the drug candidate to potentially treat immunological diseases
It is developing the drug candidate to potentially treat immunological diseases
Huntington Medical Research Institutes present first-of-its-kind study examining impact of erectile dysfunction drugs on major adverse cardiovascular events and mortality
Q1 net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
Peacock also serves as a Director and Chair of the Audit and Finance Committee of UCB SA, a biopharmaceutical company focusing on neurology and immunology
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation Protein Footprinting Systems.
The company also raised Rs 270 crore investment from Temasek in 2019
Cipla has reported consolidated financial results for the period ended March 31, 2022
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Subscribe To Our Newsletter & Stay Updated
